// App-Quantinova.ai

647 : Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma

Researchers

Presenter

  • Don Stevens

Principal Investigators

  • Clifton Mo

  • Benjamin Garmezy

  • John Hamm

  • Benedito Carneiro

  • Breelyn Wilky

  • Rachel Sanborn

  • Anthony El- Khoueiry

  • Alexa Buffa

  • Sonia De Munari

  • Burcu Yigit

  • Marco Purbhoo

  • Mark Exley

  • David Einstein

Medical Centers

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Dana-Farber Cancer Institute, Boston, MA

  • Sarah Cannon Cancer Institute Nashville, Nashville, TN, USA

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Lifespan Cancer Institute (LCI), Providence, RI

  • MiNK Therapeutics, Lexington, MA, USA

  • Earle A. Chiles Research Institute, Portalnd, OR

  • Norton Cancer Institute, Louisville, KY

  • University of Colorado Cancer Center, Aurora, CO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT04754100

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved